Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Kelly Anne Phillips, Julie Aldridge, Karin Ribi, Zhuoxin Sun, Alastair Thompson, Vernon Harvey, Beat Thürlimann, Fatima Cardoso, Olivia Pagani, Alan S. Coates, Aron Goldhirsch, Karen N. Price, Richard D. Gelber, Jürg Bernhard

Research output: Contribution to journalArticle

Abstract

Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5 years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1 year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change = 0.22, effect size = 0.53, P <0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalBreast Cancer Research and Treatment
Volume126
Issue number1
DOIs
Publication statusPublished - Feb 2011

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Cognitive function
  • Letrozole
  • Quality of life
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial'. Together they form a unique fingerprint.

  • Cite this

    Phillips, K. A., Aldridge, J., Ribi, K., Sun, Z., Thompson, A., Harvey, V., Thürlimann, B., Cardoso, F., Pagani, O., Coates, A. S., Goldhirsch, A., Price, K. N., Gelber, R. D., & Bernhard, J. (2011). Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Research and Treatment, 126(1), 221-226. https://doi.org/10.1007/s10549-010-1235-y